Johnson & Johnson's (JNJ) Janssen-Cilag International unit said Wednesday that the European Commission has approved an indication extension of Imbruvica, or ibrutinib, in frontline mantle cell lymphoma, or MCL, an aggressive and incurable form of blood cancer.
The approved regimen includes ibrutinib, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone alternating with R-DHAP or R-DHAOx without ibrutinib, followed by ibrutinib monotherapy to treat adults with previously untreated MCL who are eligible for autologous stem cell transplant, the company said.
The approval was backed by data from a phase 3 trial conducted by the European MCL Network, the company added.
After a median follow-up of 55 months, the study showed that ibrutinib combined with chemoimmunotherapy led to "significantly superior" failure-free survival even without the need for transplant, the company said.
Price: 167.26, Change: -0.67, Percent Change: -0.40
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。